

Jerónimo J. Pardo (Paediatric Emergency Department, Hospital Universitario A Coruña, La Coruña); Ester Castellarnau (Paediatric Emergency Department, Hospital Universitario Joan XXIII, Tarragona); Esther Ballester (Paediatric Emergency Department, Hospital Universitario Dr. Peset, Valencia); Lizar Aguirre (Paediatric Emergency Department, Hospital Universitario Txagorritxu, Vitoria); Abel Martínez (Paediatric Emergency Department, Hospital Universitario Tarrassa, Tarrassa); Neus Pociello (Paediatric Emergency Department, Hospital Universitario Arnau de Vilanova, Lleida); Maria A. García (Paediatric Emergency Department, Hospital Universitario Príncipe de Asturias, Alcalá de Henares); Miriam Gutiérrez (Paediatric Emergency Department, Hospital Universitario Burgos, Burgos); Pau Ventosa (Paediatric Emergency Department, Hospital Universitario General de Catalunya, Sant Cugat del Valles).

All of them submitted the initial questionnaire and collected data for the study in their respective hospitals.

## References

- Mintegi Raso S, Benito Fernández J, García González S, Corrales Fernández A, Bartolomé Albistegui MJ, Trebolazabala Quirante N. Demanda y asistencia en un servicio de urgencias hospitalario. *An Pediatr (Barc)*. 2004;61:156–61.
- Muñoz García JL, Fandiño Orgeira JM, Díaz Peromingo JA. Demanda asistencial de urgencias pediátricas atendidas en un hospital comarcal. *Aten Primaria*. 2008;40:297–301.
- IFEM International Federation of Emergency Medicine. 2012 International Standards of Care for Children in Emergency Departments [accessed 1 April 2019]. Available from: <http://www.ifem.cc/wp-content/uploads/2016/07/International-Standards-for-Children-in-Emergency-Departments-V2.0-June-2014-1.pdf>.

Roberto Velasco<sup>a,\*</sup>, Santiago Mintegi<sup>b</sup>, en representación del Grupo de Trabajo de Formación de la Red de Investigación de la Sociedad Española de urgencias de Pediatría (RISeuP-SPERG)<sup>1</sup>

<sup>a</sup> *Unidad de Urgencias de Pediatría, Hospital Universitario Río Hortega, Valladolid, Spain*

<sup>b</sup> *Urgencias de Pediatría, Hospital Universitario Cruces, Universidad del País Vasco, Baracaldo, Spain*

\*Corresponding author.

E-mail address: [robertovelascozuniga@gmail.com](mailto:robertovelascozuniga@gmail.com)

(R. Velasco).

<sup>1</sup> The members of the Training Working Group of the Research Network of the Spanish Society of Pediatric Emergencies (RISeuP-SPERG) are presented in Appendix A.

<https://doi.org/10.1016/j.anpede.2019.06.015>  
2341-2879/

© 2020 Published by Elsevier España, S.L.U. on behalf of Asociación Española de Pediatría. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

## Clinical features and origin of cases of parotiditis in an emergency department<sup>☆</sup>



### Caracterización clínica y etiológica de los casos de parotiditis en un servicio de urgencias

To the editor:

The mumps virus (MuV), or *Myxovirus parotiditis*, continues to cause sporadic cases and outbreaks of disease. This is associated to the progressive waning of immunity against the mumps component of the measles, mumps, rubella (MMR) vaccine in absence of a natural booster (especially from 10 years after administration of the second dose), the use in the 1993–1999 period of a vaccine that had the Rubini strain, which proved to be less effective, and the presence of pockets of unvaccinated people in the population.<sup>1</sup> In Spain, 10 260 cases were notified in 2017 and 8996 in 2018, a significant increase compared to previous seasons.<sup>2</sup>


Some of the infectious agents other than MuV that may be involved in parotiditis as a general clinical presentation include influenza A virus, parainfluenza virus, Epstein-Barr virus (EBV), adenovirus, coxsackievirus, cytomegalovirus

(CMV), parvovirus B19, herpesvirus and lymphocytic choriomeningitis virus, as well as gram-positive bacteria, atypical mycobacteria and *Bartonella* species.<sup>3–5</sup> In the paediatric population, these pathogens are probably more frequent causative agents compared to MuV. This, combined with the benign course of most presentations, leads many paediatric health care facilities to make the diagnosis without an aetiological investigation. The aim of our study was to establish the viruses involved in cases of parotiditis in our area.

We carried out a retrospective study through the collection of data corresponding to 2 full years (2016 and 2017), including all patients given a diagnosis of parotiditis (with swelling of the parotid glands being a requirement for inclusion) in the paediatric emergency department of a tertiary care hospital in Barcelona that manages patients up to age 16 years and based on diagnostic judgment of the paediatrician in charge of the patient. Per hospital protocol, polymerase chain reaction (PCR) tests for detection of MuV in saliva and urine samples were performed in patients with parotiditis. Serologic tests were added if blood tests were requested by the paediatrician in charge based on his or her clinical judgment. When it came to serologic testing, in case of negative results of the test for detection of MuV in saliva, molecular methods were used for detection of influenza A and B virus, respiratory syncytial virus A/B, adenovirus, metapneumovirus, coronavirus nl63/OC43/229E, enterovirus, rhinovirus, parainfluenza virus, EBV and CMV. Mump viruses were characterised by partial sequencing of the small hydrophobic (SH) gene.

We identified 169 cases of symptomatic acute parotiditis (0.21% or paediatric emergency visits). The median age of the patients was 7.7 years (range, 11 months–16.8 years).

<sup>☆</sup> Please cite this article as: Scatti-Regàs A., Aguilar-Ferrer M.C., Antón-Pagarolas A., Martínez-Gómez X., González-Peris S. Caracterización clínica y etiológica de los casos de parotiditis en un servicio de urgencias. *An Pediatr (Barc)*. 2020;93:127–129.



**Fig. 1** Results of PCR testing of saliva samples expressed as absolute frequencies and percentages of the total samples obtained from 134 patients.

**Table 1** Summary of demographic and clinical characteristics and management of cases of parotitis with an identified aetiological agent.

Variable <i>n</i> (%) <sup>a</sup>	Mumps virus <sup>b</sup> <i>n</i> = 18 (38.3%) <sup>c</sup>	EBV <i>n</i> = 21 (44.7%) <sup>c</sup>	CMV <i>n</i> = 11 (23.4%) <sup>c</sup>	Influenza A H3N2 <i>n</i> = 6 (12.8%) <sup>c</sup>	Parainfluenza 2 and 3 <i>n</i> = 4 (8.5%) <sup>c</sup>	Total with aetiological diagnosis <i>n</i> = 47
Female sex; <i>n</i> (%)	5 (27.8)	5 (23.8)	3 (27.2)	3 (50)	0 (0)	14 (30)
Median age; (range)	14.3 (1.5–16.8) <sup>d</sup>	7.5 (1.5–14.9) <sup>d</sup>	7.5 (1.4–14.4) <sup>d</sup>	11.6 (6.5–13.6) <sup>d</sup>	2.6 (0.9–4.8) <sup>d</sup>	8.58 (0.9–16.8) <sup>d</sup>
Bilateral involvement; <i>n</i> (%)	2 (11.1)	3 (14.3)	2 (18.2)	2 (33.3)	0 (0)	6 (12.8)
Submandibular swelling; <i>n</i> (%)	3 (16.6)	4 (19.0)	3 (27.2)	3 (50)	0 (0)	10 (21.3)
Reported pain; <i>n</i> (%)	13 (72.2)	10 (47.6)	8 (72.7)	5 (83.3)	1 (25)	30 (63.8)
Preceding or concomitant cold symptoms; <i>n</i> (%)	4 (22.2)	2 (9.5)	1 (9.1)	1 (16.7)	0 (0)	7 (14.8)
Significant lymphadenopathy; <i>n</i> (%)	5 (27.8)	9 (42.8)	4 (36.4)	2 (33.3)	1 (25)	15 (31.9)
Fever; <i>n</i> (%)	13 (72.2)	12 (57.1)	4 (36.4)	2 (33.3)	0 (0)	25 (53.2)
Cough; <i>n</i> (%)	2 (11.1)	3 (14.3)	1 (9.1)	3 (50)	2 (50)	9 (19.1)
Painful swallowing; <i>n</i> (%)	4 (22.2)	2 (9.5)	2 (18.2)	1 (16.7)	0 (0)	6 (12.8)
Blood tests based on clinician's judgment; <i>n</i> (%)	11 (61.2)	10 (47.6)	7 (63.6)	4 (66.7)	2 (50)	27 (57.4)
Empiric antibiotherapy; <i>n</i> (%)	3 (16.6)	3 (14.3)	2 (18.2)	3 (50)	0 (0)	9 (19.1)
Hospital admission; <i>n</i> (%)	1 (5.5)	1 (4.8)	2 (18.2)	0 (0)	0 (0)	3 (6.4)

CMV, cytomegalovirus; EBV, Epstein-Barr virus.

Total: 47 patients, corresponding to 35.1% of the total patients that underwent some form of testing for aetiological investigation.

The columns devoted to each individual virus include all patients with a positive test result for that virus, including cases of coinfection.

<sup>a</sup> Percentage of the total patients with a positive test for the virus corresponding to the column.

<sup>b</sup> Of the 18 cases: 13 diagnosed by PCR on saliva samples and 5 by antibody testing.

<sup>c</sup> Percentage of total patients with an etiological diagnosis.

<sup>d</sup> Age in years.

The rate of adherence to the protocol for the ordering of tests for aetiological diagnosis was 79.3%, so we were able to obtain data on testing of saliva samples from 134 patients. Fig. 1 summarises the results of PCR testing of these samples. Another 5 patients received an aetiological diagnosis of parotitis due to MuV by serologic testing (positive IgM test), adding up to a total of 18 cases caused by MuV.

The median age of patients with MuV infection (in all cases MuV genotype G) was 14.3 years (range, 18 months–16.8 years), with a predominance of the male sex (72.2%).

In 3 cases (16.7%) there was no known history of contact with a case of parotitis. All patients were correctly vaccinated save for 2 children that had not received any dose of MMR by parental choice and 1 adolescent that had only received 1 dose of vaccine. There were no documented complications, except for 1 patient that developed Guillain-Barré syndrome with onset the week after the initial visit, who had a favourable outcome. The management of 19.1% of the patients included empiric antibiotherapy despite there being no evidence confirming bacterial infection.

Table 1 presents the demographic and clinical characteristics of cases of parotitis in which testing was performed for investigation of the aetiology. Patients with MuV infection were significantly older compared to children with a different aetiological agent (median age, 14.3 vs 6.5 years;  $P = .005$ ).

The findings in our study, despite the limitations intrinsic to its retrospective design, were consistent with those of other authors, and showed that a significant proportion of cases of parotitis in the paediatric age group may be caused by viruses other than MuV (such as EBV, CMV and common respiratory viruses).<sup>3-5</sup> The high frequency of cases with negative results in all tests can be explained by the involvement of other viruses that were not included in the testing (such as human herpesvirus 6), technical factors affecting the yield of microbiological diagnosis and the potential presence of non-infectious parotitis cases, among others. Viral coinfection was also frequent.

Lastly, we ought to underscore that MuV continues to be a frequent cause of parotitis in our area (especially in older children), even in correctly vaccinated patients, and our findings confirmed that the causative virus continues to circulate in the community with a well-known pattern characterised by incidence peaks every 3–5 years. The aetiological diagnosis and notification of cases can alert the health care authorities of potential outbreaks at an early stage, allowing implementation of containment measures such as administration of a third dose of vaccine in selected patients.<sup>6</sup>

## References

1. Vygen S, Fischer A, Meurice L, Mouchetrou Njoya I, Gregoris M, Ndiaye B, et al. Waning immunity against mumps in vaccinated young adults, France 2013. *Euro Surveill.* 2016;21(10):30156.
2. Boletín epidemiológico semanal Instituto de Salud Carlos III: <http://www.isciii.es/ISCIII/es/contenidos/fd-servicios->

cientifico-tecnicos/fd-vigilancias-alertas/fd-boletines/fd-boletin-epidemiologico-semanal-red/pdf.2018/IS-180123-WEB.pdf. Consultado el 15 de mayo de 2019.

3. Elbadawi LI, Talley P, Rolfes MA, Millman AJ, Reisdorf E, Kramer NA, et al. Non-mumps Viral Parotitis During the 2014-2015 Influenza Season in the United States. *Clin Infect Dis.* 2018;67(4):493–501.
4. Shepherd SJ, MacLean AR, Aitken C, Gunson RN. Letter to the editor: there is a need to consider all respiratory viruses in suspected mumps cases. *Euro Surveill.* 2015;20(33):21210.
5. Barrabeig I, Costa J, Rovira A, Marcos MA, Isanta R, López-Adalid R, et al. Viral etiology of mumps-like illnesses in suspected mumps cases reported in Catalonia, Spain. *Hum Vaccin Immunother.* 2015;11(1):282–7.
6. Cardemil CV, Dahl RM, James L, Wannemuehler K, Gary HE, Shah M, et al. Effectiveness of a Third Dose of MMR Vaccine for Mumps Outbreak Control. *N Engl J Med.* 2017;377(10):947–56.

Aina Scatti-Regàs<sup>a</sup>, Marta Carmen Aguilar-Ferrer<sup>a</sup>, Andrés Antón-Pagarolas<sup>b</sup>, Xavier Martínez-Gómez<sup>c</sup>, Sebastià González-Peris<sup>a,✉#x204e;</sup>

<sup>a</sup> Unidad de Urgencias Pediátricas, Hospital Infantil Vall d'Hebron, Barcelona, Spain

<sup>b</sup> Unidad de Virus Respiratorios, Servicio de Microbiología, Hospital Vall d'Hebron, Barcelona, Spain

<sup>c</sup> Servicio de Medicina Preventiva, Hospital Vall d'Hebron, Barcelona, Spain

\*Corresponding author.

E-mail address: [sgonzalezperis@gmail.com](mailto:sgonzalezperis@gmail.com) (S. González-Peris).

9 July 2019 18 November 2019

<https://doi.org/10.1016/j.anpede.2019.11.007>  
2341-2879/

© 2019 Asociación Española de Pediatría. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

## Impact of whooping cough vaccine during pregnancy on the resurgence of the disease and its form of presentation in paediatric emergency departments ☆,☆☆



## Impacto de la vacunación en embarazadas sobre la reemergencia de la tosferina y su forma de presentación en urgencias

Dear Editor:

Pertussis is a disease that has the most severe presentation in the first 6 months of life.<sup>1</sup> Recently, there has been a

progressive increase in the incidence of pertussis in developed countries, including severe cases in infants.<sup>2</sup> This trend has spurred the implementation of new vaccination strategies to prevent pertussis, such as vaccination of pregnant women in the third trimester of gestation. This is the most cost-effective strategy to prevent severe cases in infancy.<sup>3</sup> Vaccination of pregnant women prevents between 78% and 91% of cases of pertussis in infants aged less than 2 months<sup>4</sup> and is 90% effective in preventing hospital admission.<sup>5</sup> In February 2015, the Basque Country introduced routine vaccination of all pregnant women in the region, and the vaccination coverage rate achieved since has been estimated at 80%.<sup>6</sup>

The aim of our study, approved by the Ethics Committee of our hospital (CEIC Code E15/32), was to analyse the impact of vaccination of pregnant women against pertussis on the resurgence of this disease and the severity of disease in the paediatric emergency department (PED) of a tertiary care hospital.

We conducted a retrospective cohort study between 2008 and 2018 in the PED of a tertiary care hospital that manages approximately 55 000 emergency visits a year of children aged less than 14 years. We compared the characteristics and discharge destination of patients with a microbiological diagnosis of pertussis (species-specific polymerase chain

☆ Please cite this article as: Gangoiti I, Martínez-Fernández E, Garmendia O, Diez A, Mintegi S. Impacto de la vacunación en embarazadas sobre la reemergencia de la tosferina y su forma de presentación en urgencias. *An Pediatr (Barc).* 2020;93:129–131.

☆☆ Previous presentations: This study was presented at the XXIV Annual Meeting of the Sociedad Española de Urgencias de Pediatría and the 67th Congress of the Asociación Española de Pediatría.